Abstract
Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 351-355 |
| Number of pages | 5 |
| Journal | Advances in Nutrition |
| Volume | 8 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2017 |
Fingerprint
Keywords
- Cholesterol
- Cognition
- Infant formula
- Infection
- MFGM
- Neurodevelopment
- Otitis
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Food Science
- Nutrition and Dietetics
Cite this
Supplementation of infant formula with bovine milk fat globule membranes. / Timby, Niklas; Domellöf, Magnus; Lönnerdal, Bo; Hernell, Olle.
In: Advances in Nutrition, Vol. 8, No. 2, 01.03.2017, p. 351-355.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Supplementation of infant formula with bovine milk fat globule membranes
AU - Timby, Niklas
AU - Domellöf, Magnus
AU - Lönnerdal, Bo
AU - Hernell, Olle
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.
AB - Studies have shown that supplementation of infant formula with bovine milk fat globule membranes (MFGMs) may substantially narrow the gap in health outcomes between formula-fed and breastfed infants. In one study, consumption of a formula supplemented with a lipid-rich MFGM concentrate between 2 and 6 mo ofage improved cognitive performance at 24 wkofage. In another study, a formula supplemented with a protein- rich MFGM concentrate given between 2 and 6 mo ofage improved cognitive performance at 12 mo ofage, decreased infectious morbidity until 6 mo ofage, and yielded serum cholesterol concentrations closer to those of breastfed infants. A third study that assessed the safety ofsupplementing infant formula with a lipid-rich or a protein-rich MFGM concentrate found a noninferior weight gain for both groups compared with a nonsupplemented formula. In this study, therewas an increased riskofeczema in the protein-rich group, but no seriousadverseevents. Infantformulas with supplemental MFGMs have been launched on the market in several countries. However, the evidence base must still be considered quite limited. Based on 3 randomized controlled trials that are not comparable, the intervention seems safe, but there is not enough evidence for a general recommendation on which MFGM fraction to use and at what concentration as formula supplement for a given outcome.
KW - Cholesterol
KW - Cognition
KW - Infant formula
KW - Infection
KW - MFGM
KW - Neurodevelopment
KW - Otitis
UR - http://www.scopus.com/inward/record.url?scp=85020185541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020185541&partnerID=8YFLogxK
U2 - 10.3945/an.116.014142
DO - 10.3945/an.116.014142
M3 - Review article
C2 - 28298277
AN - SCOPUS:85020185541
VL - 8
SP - 351
EP - 355
JO - Advances in Nutrition
JF - Advances in Nutrition
SN - 2161-8313
IS - 2
ER -